J. Li

发表

RAV 12 Accelerates the Desensitization of Akt / PKB Pathway of Insulin-like Growth Factor I Receptor Signaling in COLO 205

J. Li, Rong-shan Li, 2007 .

RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205.

J. Li, Rong-shan Li, 2007, Cancer research.

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

P. Moore, Syd Johnson, S. Burke, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Development of an Fc-Enhanced Anti – B 7-H 3 Monoclonal Antibody with Potent Antitumor Activity

P. Moore, Syd Johnson, S. Burke, 2012 .

Reprogramming human T cell function and specificity with non-viral genome targeting

Channabasavaiah B. Gurumurthy, Rolen M. Quadros, A. Ashworth, 2017, bioRxiv.

A Cas9 nanoparticle system with truncated Cas9 target sequences on DNA repair templates enhances genome targeting in diverse human immune cell types

Daniel B. Goodman, J. Puck, J. Bluestone, 2019, bioRxiv.

Abstract B269: Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET

J. Li, Lora Zhao, V. Vysotskaia, 2009 .

Abstract 330: Targeting B7-H3 in prostate cancer: Preclinical proof of concept with MGC018, an investigational anti-B7-H3 antibody-drug conjugate

P. Moore, J. Li, S. Koenig, 2022, Cancer Research.

Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer

P. Moore, A. Adami, S. Burke, 2018, Molecular Cancer Therapeutics.